Compare · ABBV vs MPLT
ABBV vs MPLT
Side-by-side comparison of AbbVie Inc. (ABBV) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $401.47B, about 316.1x MPLT ($1.27B).
- ABBV has been more active in the news (10 items in the past 4 weeks vs 3 for MPLT).
- ABBV has more recent analyst coverage (25 ratings vs 10 for MPLT).
- Company
- AbbVie Inc.
- MapLight Therapeutics Inc.
- Price
- -
- -
- Market cap
- $401.47B
- $1.27B
- 1M return
- +11.65%
- -
- 1Y return
- +19.69%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2025
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 10
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest MPLT
- UBS initiated coverage on MapLight Therapeutics with a new price target
- Craig Hallum initiated coverage on MapLight Therapeutics with a new price target
- Chief Executive Officer Kroeger Christopher A. sold $3,215,000 worth of Voting Common Stock (118,235 units at $27.19) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 1,394,094 units (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Chief Medical Officer Foff Erin Pennock sold $126,640 worth of Voting Common Stock (4,438 units at $28.54) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 346,059 units (SEC Form 4)
- General Counsel Hanson Kristopher sold $419,263 worth of Voting Common Stock (13,917 units at $30.13) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 162,331 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. sold $1,949,634 worth of Voting Common Stock (68,491 units at $28.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,512,329 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff sold $20,390 worth of Voting Common Stock (721 units at $28.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.30% to 242,729 units (SEC Form 4)